Skip to main content
Premium Trial:

Request an Annual Quote

Prolexys and Arizona Biodesign Institute Enter Proteomics Collaboration

NEW YORK, April 6 (GenomeWeb News) - Prolexys Pharmaceuticals (formerly Myriad Proteomics) has signed a proteomics-based research collaboration with the Arizona Biodesign Institute at Arizona State University, the company said today.

The researchers will work together to discover peptides and small molecules that modulate vascular tone, with the goal of developing therapies to prevent certain types of stroke as well as the vasodilatory shock associated with hypothermia and sepsis. The project goal is to "produce promising lead candidates within the year," Prolexys said.

The collaboration is based on studies at the Arizona Biodesign Institute involving signal transduction pathways leading to vasorelaxation. Prolexys will use its peptide-based pull-down approach to characterize and isolate interacting proteins in the pathway. These proteins will be used to create assays to screen for modulators of the vasodilation process in smooth muscle, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.